The year 2020 has seen promising new data from randomized phase III trials in the field of LARC management. Nowadays, TNT strategy has been accepted as the primary treatment for LARC. The role of de-escalation strategies is still unknown. The goal is to achieve better survival outcomes with improving quality of life. Only selected patients are likely to benefit from NOM or immunotherapy alone.
Keyphrases
- phase iii
- open label
- rectal cancer
- locally advanced
- double blind
- clinical trial
- placebo controlled
- phase ii
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- neoadjuvant chemotherapy
- newly diagnosed
- prognostic factors
- big data
- patient reported outcomes
- electronic health record
- combination therapy
- machine learning
- quality improvement
- artificial intelligence